The Hong Kong office of global law firm Eversheds has advised BOCI Asia Limited in connection with the HK$1.09 billion initial public offering of Consun Pharmaceutical Group Limited in Hong Kong. The company was succeesfully listed on 19 December 2013.

Consun Pharmaceutical Group Limited is an integrated pharmaceutical company principally engaged in the research, manufacturing and sale of modern Chinese medicines and medical contrast medium in the PRC. Its key product, uremic clearance granule, is the leading modern Chinese medicine for treating kidney disease in the PRC.

The company raised HK$1.09 billion by issuing 250 million shares, which represent 25% of the company’s total issued share capital immediately after the completion of the IPO, at HK$4.36 each. The Hong Kong public offering has been over-subscribed by approximately 130 times.

BOCI Asia Limited, as the sole global coordinator, bookrunner, sponsor and lead manager, has appointed Eversheds to represent it in this IPO.

The Eversheds team has been led by Partners Stephen Mok and Norman Hui, assisted by Grace Leung, Karen Wang, Man-Wai Wong and Jocelyn Chow.

Commenting on this IPO, Stephen Mok said;

“BOCI Asia is a long standing client of the firm, who we have advised on several matters in recent months. We look forward to continuing our partnership with them as the Asian IPO market continues to gather pace.”